AstraZeneca, Theragnostics sign PARPi development agreement
The licensing agreement enables the company’s “freedom to operate globally in the diagnostic field of certain selected radionuclide-labelled PARPi”.
Read More
Tag: Theranostics
New late stage prostate cancer technology available in UK
The technology, called Theranostics, provides a personalised approach to treatment and diagnosis in prostate cancer.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
